All patients deserve access to the right testing & treatment at the right time

From Testing to Targeted Treatment Program (FT3) is a non-profit multi-stakeholder collaborative program that aims to unify, accelerate and build on existing efforts to make precision medicine a reality for all patients who could benefit from it. Co-led by patients, FT3 is strongly focused on patient needs and experiences.

All patients deserve access to the right testing & treatment at the right time

From Testing to Targeted Treatment Program (FT3) is a collaborative program to make precision medicine a reality for all patients who could benefit from it.

All patients deserve access to the right testing & treatment at the right time

Participate now in a public consultation for the co-created Precision Medicine Patient Stories Library

Program highlights

Now available for testing and feedback

Download and test the Access Barrier Cause-Effect Canvas.

 

Now available for testing and feedback

Participate now in a public consultation for the co-created Country and Condition Cards for Precision Medicine.

DNA tests for tumours can be a game-changer

Patient story: A cutting-edge DNA test put Inke Logtenberg on the right treatment path. Now she hopes others with Cancer of Unknown Primary (CUP) will have swift access to personalized care

About us

Our motivation

All patients deserve access to the right testing & treatment at the right time. While Precision Medicine (PM) can transform lives, its potential benefits have not yet been fully realized.

Our ambition

Our goal is to improve access to precision medicine for all patients who could benefit from it, by generating better evidence, creating awareness and building the conditions for better access, starting with testing and cancer.

The partnership

We are an independent, nonprofit, global and multistakeholder consortium, building solutions with patients, for patients. Its members and community include individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.

Keep up to date with developments from the precision medicine ecosystem

We don’t spam. Just key info at the right time.